Liotironina

Regulatory sources consulted

• AEMPS CIMA Ficha Técnica: 45503 (https://cima.aemps.es/cima/dochtml/ft/45503/FT_45503.html)
• AEMPS CIMA · nº registro 45503 ↗

Approved indications

• Treatment of hypothyroidism of any etiology (except transient hypothyroidism during the recovery phase of subacute thyroiditis). Also indicated for simple (non-endemic) goiter, chronic lymphocytic thyroiditis (Hashimoto's), myxedema, cretinism, thyroid aplasia, and as replacement therapy after thyroidectomy or radioactive iodine therapy. It is used in the thyroid suppression test for the differential diagnosis of hyperthyroidism.

Contraindications

Clinical warnings

• Major warning · Use with extreme caution in patients with cardiovascular disease (e.g., angina, hypertension, arteriosclerosis) and in the elderly. Start with low doses. — AEMPS CIMA
• Patients with diabetes mellitus or insipidus, or adrenal insufficiency, may experience a worsening of their symptoms upon starting therapy. — AEMPS CIMA

Drug interactions

• ModerateOral anticoagulantsB01AA

  Mechanism: Thyroid hormones increase the catabolism of vitamin K-dependent coagulation factors, potentiating the anticoagulant effect.

  Recommendation: Closely monitor prothrombin time (INR) when starting, changing, or discontinuing liothyronine therapy and adjust the anticoagulant dose as needed.

  AEMPS CIMA

• ModerateInsulin or oral antidiabeticsA10

  Mechanism: Liothyronine may increase insulin or oral antidiabetic requirements.

  Recommendation: Monitor blood glucose when starting thyroid therapy and adjust the antidiabetic dose if necessary.

  AEMPS CIMA

Adverse events

Pregnancy and lactation

FDA category: A

Thyroid replacement therapy is essential and should not be discontinued during pregnancy. Liothyronine crosses the placenta in minimal amounts. It is excreted in breast milk in low concentrations, but caution should be exercised.